Prolonged Marketing And Distribution Agreement For Aftamed

Navamedic ASA (Lysaker, Norway, 26 June 2008) Navamedic's subsidiary Vitaflo Scandinavia has signed a prolonged marketing and distribution agreement with Bioplax for the product Aftamed. Vitaflo has marketed and sold Aftamed since December 2006, and has now the right to the product in Sweden, Norway, Denmark and Finland until 2013. Aftamed was in 2007 among the 3 largest products in Vitaflo's portfolio. With this new agreement, all the most important marketing and distribution agreements have a remaining duration of minimum 5 years.

Aftamed is used in the treatment of mouth ulcers.

For further information, please contact: Øyvind W. Brekke, CEO Navamedic ASA E-mail: oyvind.brekke@navamedic.com Office: +47 67 11 25 40 Mobile: +47 91 19 81 64

Roland Sandström, COB Vitaflo Scandinavia AB E-mail: roland.sandstrom@vitaflo.net Office: +46 31 335 1190 Mobile: +46 70 5925 622

Bernt-Olav Røttingsnes, CFO/IRO Navamedic ASA E-mail: bor@navamedic.com Office: +47 67 11 25 44 Mobile: +47 91 34 70 21

Navamedic ASA

http://www.navamedic.com

ISIN: NO0010205966

Stock Identifier: XOSL.NAVA